Implications of Clinical and Biochemical Parameters of COVID-19 Patients in Disease Severity And its Outcome
Abstract
Background and Objectives: COVID-19 pandemic has affected humanity in an unprecedented way. The present study aims to evaluate the various clinical, demographic, biochemical parameters in a tertiary care hospital in Jammu and Kashmir.
Methods: In this descriptive study, data of 1417 COVID-19 patients admitted in a single center from 22nd March to 30th of October 2020 was analyzed retrospectively. Severe illness was defined as a composite endpoint of admission to an intensive care unit (ICU), use of mechanical ventilation, or death or in terms of severity of disease as assessed by radiographic involvement in HRCT Chest and the need of oxygen thereafter. We analyzed the data by dividing the hospital admissions into 2 groups- group A and group B based on their admission concerning the peak of the pandemic.
Results: 1417 patients were included in this study, 66.05% of them were males (n=936). The mean age of the patients under study was 48.13± 17.68 years. Group A included patients admitted from March to June and group B included patients from July to October. Group A had 409 patients and Group B had 1008 patients. In Group A, 17.11% (70) patients had severe illnesses. In Group B, 37.9% (383) patients had severe illnesses. In group A, 382(93.4%) patients recovered and were discharged from the hospital. 27 patients (6.6%) expired. In group B, 96 patients (9.5%) with severe disease expired, the remaining 912 patients were discharged from the hospital.
Conclusion: Early months of the pandemic presented with less disease burden. The majority of the patients were having mild asymptomatic disease and only a lesser fraction of the patients presented with severe pneumonia. The peak pandemic period was associated with increased mortality and disease burden.
Downloads
References
2. Lu H, Stratton CW, Tang YW, Outbreak of Pneumonia of Unknown Etiology in Wuhan, China. The mystery and miracle, J Med Virol(Jan,16(2020)) 401-402. doi:10.1002/jmv.25678
3. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Eng J Med. 382 (Feb 8,)(2020) 727-733. https:/doi.org/10.1056/NEJM0A2001017.
4. World Health Organisation, Novel Coronavirus (2019-COV) situation report 11, Feb 2020 and WHO-Director General’s remarks at the media on 11, Feb 2020.
5. Lu R, Zhao X, Li J, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus; implications for virus origins and receptor binding. The Lancet 395 (Feb (10224)) (2020) 565-574.https://doi.org/10.1016/S0140-6736(20).
6. WHO Director General’s opening remarks at the media briefing on Covid-19; 11 March 2020. Published March 11, 2020 https://www.int/dg/speeches/detact/who-director-general-s-opening remarks -at-the-media-briefing-on- covid19-11-march- 2020.
7. W.Guan, Z.Ni, Y.Hu Nu et al. Clinical characteristics of Coronavirus Disease 2019 in China. N. Engl J Med. 2020 3012:1708-20. DOI:10.1056/NEJM oa 2002 032.
8. C. Huang, Y. Wang, X. Li et al. Clinical features of the patients infected with 2019, novel Coronavirus in Wuhan, China. The Lancet 2020: 3 95 (10223): 497-506. doi:10.1016/50140-6736 (20) 30183-5.
9. D. Wang, B. C.Hu et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus infected pneumonia in Wuhan, China. JAMA 2020: 323 (11): 1061-1069.doi: 10.1001/jama. 2020.1585.
10. N.Chen, M.Zhou, X-Dong, et al. Epidemological and Clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China; a descriptive study. The Lancet 395(Feb(10233))(2020)507-513. http://doi.org/10.1016/S01 40- 6736(20)30211-7.
11. J.P. Metlay, G.W. Waterer, A.C. Long, et al. Diagnosis and treatment of adults with community pneumonia; an official clinical practice guideline of the American Thoracic Society and Infectious Disease Society of America. Am J Respir Crit Care Med 2019; 200(7): e45-e67.
12. V.M.Renieri, G.D.Ruben feld,B.T.Thompson; et al; ARDS Definition Task Force. Acute respiratory distress syndrome: the Berlin definition, JAMA 2012; 307 (23): 2526-2533 doi: 10,1001/JAMA,2012 5669.
13. Lionel A. Mandell, Richard G. Wunderin k,et al. Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults . 2007. CID 2007:44
14. Thirumalaisamy P. Velavana, Christian G. Meyera. Mild versus severe COVID-19: Laboratory markers. International Journal of Infectious Diseases95(2020). 304 -307.
15. Henry BM. COVID-19, ECMO, and lymphopenia: a word of caution. Lancet Respir Med; 2020.
16. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China. Lancet. 2020;395:497–506.
17. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan. China: a retrospective cohort study. Lancet 2020;.
18. Mark Joy, FD Richard Hobbs, Jamie Lopez Bernal, Excess mortality in the first COVID pandemic peak: cross-sectional analyses of the impact of age, sex, ethnicity, household size, and long-term conditions in people of known
This work is licensed under a Creative Commons Attribution 4.0 International License.
